US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
INmune Bio Inc. - Common stock
(NQ:
INMB
)
1.930
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about INmune Bio Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
September 14, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Present at the H.C. Wainwright Global Investment Conference
September 09, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
August 26, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio (INMB) Q2 2026 Earnings Call Transcript
↗
August 07, 2026
Ebstracel nears UK filing as XPro shows Alzheimer's biomarker progress.
Via
The Motley Fool
Topics
Earnings
INmune Bio (NASDAQ:INMB) Beats Q2 Loss Estimates but Shares Tumble on Business Update
↗
August 06, 2026
Via
Chartmill
INMUNE BIO INC (NASDAQ:INMB) Beats Q1 2026 EPS Estimates as Stock Shows Recent Momentum
↗
May 07, 2026
Via
Chartmill
INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial?
↗
February 12, 2026
Via
Stocktwits
INmune Bio Q2 Earnings Call Highlights
↗
August 06, 2026
INmune Bio (NASDAQ:INMB) outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026,...
Via
MarketBeat
Topics
Earnings
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
July 31, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
July 31, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
July 30, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
July 20, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
July 15, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
July 09, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
July 01, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
June 25, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
June 23, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
June 02, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio (INMB) Q4 2025 Earnings Transcript
↗
June 01, 2026
INmune Bio (INMB) Q4 2025 Earnings Transcript
Via
The Motley Fool
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
May 15, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
May 14, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
May 13, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio (INMB) Q1 2026 Earnings Transcript
↗
May 08, 2026
INmune Bio (INMB) Q1 2026 Earnings Transcript
Via
The Motley Fool
Topics
Economy
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
May 05, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
April 30, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
April 16, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
March 24, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
March 19, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
February 23, 2026
Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
February 19, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
